As enhanced atrial superoxide production is a self-perpetuating process (36) that increases myocardial oxygen consumption, β-adrenergic responsiveness, and thrombogenic risk linked to AF (37–39), our findings suggest that increasing atrial apelin bioavailability may represent a strategy for preventing and treating AF. This evidence concerns the gene APLN and atrial fibrillation.